SCHEMBL20165547

SCHEMBL20165547

Oc1c(Br)ccc(C(F)(F)F)c1F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 2/20 0.37
NOTUM Q6P988 2/20 0.36
MAPT P10636 4/20 0.36
LMNA P02545 3/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
XBP1 P17861 1/20 0.36
HTT P42858 2/20 0.34
EPHX1 P07099 2/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
TMPRSS4 Q9NRS4 1/20 0.34
SMN1; SMN2 Q16637 3/20 0.33
TAS2R14 Q9NYV8 1/20 0.33
PDE2A O00408 1/20 0.32
CYP11B1 P15538 1/20 0.32
CYP11B2 P19099 1/20 0.32
CES2 O00748 1/20 0.31
GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31507812 0.83 KIF11 (0.37) KIF11NOTUMMAPTLMNAMEN1
SCHEMBL3838860 0.83 KIF11 (0.37) KIF11NOTUMMAPTLMNAMEN1
SCHEMBL30730980 0.79 PDE2A (0.38) KIF11NOTUMMAPTLMNAMEN1
SCHEMBL1568066 0.79 PDE2A (0.38) KIF11NOTUMMAPTLMNAMEN1
SCHEMBL29490962 0.77 KIF11 (0.44) KIF11TMPRSS4PDE2ACES2
SCHEMBL26523712 0.77 KIF11 (0.44) KIF11TMPRSS4PDE2ACES2
SCHEMBL21487292 0.77 NOTUM (0.35) KIF11NOTUMMAPTLMNAMEN1
SCHEMBL10974687 0.74 EPAS1 (0.37) NOTUMTMPRSS4PDE2ACYP11B1CYP11B2
SCHEMBL29490992 0.74 KIF11 (0.33) KIF11NOTUM
SCHEMBL30053746 0.74 EPAS1 (0.37) NOTUMTMPRSS4PDE2ACYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4611743-A1 TRIAZINES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 Merck Sharp & Dohme LLC (US) 2025-09-10 EP disclosed
EP-4189036-B1 DIBENZOFURAN AND DIBENZOTHIOPHENE DERIVATIVES MERCK PATENT GMBH (DE) 2025-06-18 EP disclosed
WO-2024097598-A1 TRIAZINES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 MERCK SHARP & DOHME LLC (US) 2024-05-10 WO disclosed
EP-4279565-A2 THIOPHENE COMPOUND, LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME Merck Patent GmbH (DE) 2023-11-22 EP disclosed
EP-4279565-A2 THIOPHENE COMPOUND, LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME Merck Patent GmbH (DE) 2023-11-22 EP disclosed
CN-109554181-B Liquid crystal medium and liquid crystal display comprising same 默克专利股份有限公司 2023-10-31 CN disclosed
EP-3763802-B1 THIOPHENE COMPOUND, LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME MERCK PATENT GMBH (DE) 2023-09-06 EP disclosed
EP-3763802-B1 THIOPHENE COMPOUND, LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME MERCK PATENT GMBH (DE) 2023-09-06 EP disclosed
CN-109207161-B Liquid crystal medium and liquid crystal display comprising same 默克专利股份有限公司 2023-08-22 CN disclosed
CN-110023457-B Liquid crystal medium and liquid crystal display comprising same 默克专利股份有限公司 2023-08-18 CN disclosed
EP-3541892-A1 LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME Merck Patent GmbH (DE) 2019-09-25 EP disclosed
CN-110023457-A Liquid crystal media and liquid crystal display comprising it 默克专利股份有限公司 2019-07-16 CN disclosed
WO-2019076899-A1 LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME MERCK PATENT GMBH (DE) 2019-04-25 WO disclosed
US-20190093013-A1 LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME MERCK PATENT GMBH (DE) 2019-03-28 US disclosed
EP-3460025-A1 LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME Merck Patent GmbH (DE) 2019-03-27 EP disclosed
EP-3460025-A1 LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME Merck Patent GmbH (DE) 2019-03-27 EP disclosed
US-20190002430-A1 LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME MERCK PATENT GMBH (DE) 2019-01-03 US disclosed
EP-3421570-A1 LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME Merck Patent GmbH (DE) 2019-01-02 EP disclosed
EP-3421570-A1 LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME Merck Patent GmbH (DE) 2019-01-02 EP disclosed
WO-2018091489-A1 LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME MERCK PATENT GMBH (DE) 2018-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190002430-A1 LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME NEFM, FES, LSS KIF11 158/4885NOTUM 2942/4885MAPT 208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.